Human Uterus Cancer Lysates

Ordering Info:
Normal Lysates: $125.00 per 100ug vial
Tumor Lysates: $175.00 per 100ug vial
Matched Normal / Tumor Lysate set: $270.00 (10% off)
Volume Pricing:
2-8 random vials (or 1-4 matched sets): 10% off
9-20 random vials (or 5-10 matched sets): 15% off
>20 random vials (or > 10 matched sets): 20% off
ORDER NOW

Histologic types of cervical cancer include the following:

Carcinosarcoma (mixed mesodermal sarcomas - 50%), Leiomyosarcoma (30%), Endometrial stromal sarcoma (15%).

The new uterine neoplasm classification of the International Society of Gynecologic Pathologists uses the term carcinosarcoma for all primary uterine neoplasms containing malignant elements of both epithelial and stromal light microscopic appearances, regardless of whether or not malignant heterologous elements are present.

Human Uterus Cancer Lysates

Catalog Number

Diagnosis

Grade

Stage

TNM

Sex

Age

T6-001

Endometrial adenocarcinoma

1

IIIc

T2N1M0

F

52

T6-002

Endometrial adenocarcinoma

2

Ic

T1N0M0

F

60

T6-003

Mixed Mullerian carcinosarcoma

3

n/a

n/a

F

48

T6-004

Uterine fibroma

n/a

n/a

n/a

F

36

T6-005

Uterine adenocarcinoma

n/a

n/a

n/a

F

50

T6-006

Endometrial carcinoma

3

Ib

T1bN0Mx

F

74

T6-007

Endometrial adenocarcinoma

1

n/a

n/a

F

30

T6-008

Uterine adenocarcinoma

2

n/a

n/a

F

52

T6-009

Uterine adenocarcinoma

2

n/a

n/a

F

72

T6-010

Uterine adenocarcinoma

2

IIa

n/a

F

55

T6-011

Uterine adenocarcinoma

2

n/a

n/a

F

60

T6-012

Endometrial adenocarcinoma

4

n/a

n/a

F

76

T6-013

Uterine Stromal cell sarcoma

n/a

n/a

n/a

F

55

T6-014

Uterine Choriocarcinoma

n/a

n/a

n/a

F

47

T6-015

Uterine Leiomyosarcoma

1

n/a

n/a

F

40

T6-016

Adenosquamous cell uterine carcinoma

n/a

n/a

n/a

F

54

T6-017

Uterine Leiomyoma

n/a

n/a

n/a

F

52

T6-018

Uterine Leiomyoma

n/a

n/a

n/a

F

54

 

References:

Silverberg SG, Major FJ, Blessing JA, et al.: Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9 (1): 1-19, 1990.